tradingkey.logo

Veracyte Inc

VCYT
查看詳細走勢圖
42.455USD
-0.315-0.74%
交易中 美東報價延遲15分鐘
3.36B總市值
109.66本益比TTM

Veracyte Inc

42.455
-0.315-0.74%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.74%

5天

+0.99%

1月

-14.02%

6月

+60.51%

今年開始到現在

+7.21%

1年

+3.10%

查看詳細走勢圖

TradingKey Veracyte Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Veracyte Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名30/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價48.36。中期看,股價處於上升通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Veracyte Inc評分

相關信息

行業排名
30 / 404
全市場排名
102 / 4562
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 13 分析師
買入
評級
48.364
目標均價
+9.03%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Veracyte Inc亮點

亮點風險
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
業績高增長
公司營業收入穩步增長,連續3年增長50.32%
業績轉盈
公司業績轉盈,最新年度盈利美元
估值高估
公司最新PE估值110.47,處於3年歷史高位
機構減倉
最新機構持股87.37M股,環比減少1.63%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉414.70K股

Veracyte Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Veracyte Inc簡介

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
公司代碼VCYT
公司Veracyte Inc
CEOStapley (Marc A)
網址https://www.veracyte.com/

常見問題

Veracyte Inc(VCYT)的當前股價是多少?

Veracyte Inc(VCYT)的當前股價是 42.455。

Veracyte Inc 的股票代碼是什麼?

Veracyte Inc的股票代碼是VCYT。

Veracyte Inc股票的52週最高點是多少?

Veracyte Inc股票的52週最高點是50.710。

Veracyte Inc股票的52週最低點是多少?

Veracyte Inc股票的52週最低點是22.610。

Veracyte Inc的市值是多少?

Veracyte Inc的市值是3.36B。

Veracyte Inc的淨利潤是多少?

Veracyte Inc的淨利潤為24.14M。

現在Veracyte Inc(VCYT)的股票是買入、持有還是賣出?

根據分析師評級,Veracyte Inc(VCYT)的總體評級為買入,目標價格為48.364。

Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是多少

Veracyte Inc(VCYT)股票的每股收益(EPS TTM)是0.387。
KeyAI